Neko Health, co-founded by Spotify’s Daniel Ek, secured $700 million in Series C funding to accelerate growth and broaden its body scanning and health assessment services, building on prior capital raised and planning U.S. market entry.
- Raised $700M Series C led by Lightspeed Venture Partners and O.G. Venture Partners
- Technology combines body scans, bloodwork, and Apple Health data
- Plans first U.S. center in New York amid strong demand and waitlists
What happened
Neko Health, the health technology startup founded by Spotify’s Daniel Ek and Hjalmar Nilsonne, announced a $700 million Series C funding led by Lightspeed Venture Partners and O.G. Venture Partners. This latest round follows their $260 million Series B raised in early 2025. The company’s core innovation lies in proprietary body-scanning technology integrated with bloodwork analysis, providing detailed health assessments.
The startup currently operates locations in the U.K. and Sweden and is preparing to launch its first U.S. clinic in New York. To date, over 100,000 users have undergone scans, and more than 350,000 individuals are on the waitlist or have booked appointments, reflecting strong market interest in their advanced health monitoring services.
Why it matters
Neko Health’s approach combines imaging and biometric data with blood tests and integrates users’ Apple Health data, offering clinicians a more holistic and data-driven way to evaluate health outside traditional settings. This innovation supports early detection and detailed body composition analysis, including features attractive to fitness enthusiasts.
The startup’s ability to scale and expand internationally highlights growing demand for preventive health tools that leverage technology. Having high-profile testimonials, such as the detection of a malignant mole by one user, underlines the clinical relevance and real-world impact of the technology, potentially reshaping wellness and medical screening industries.
What to watch next
Market attention will focus on Neko Health’s U.S. launch in New York and how it navigates the regulatory landscape and competes with other tech-driven health scanning startups, including emerging players planning integrated wellness spa experiences. The ability to convert waiting lists into active users will also indicate consumer acceptance and demand.
Investor interest from notable backers such as Atomico, General Catalyst, and Lakestar suggests ongoing confidence in the startup’s growth potential. Monitoring additional funding rounds, user base growth, and technological advancements will provide insight into how rapidly Neko Health can expand its footprint and disrupt preventive health assessment.